Autoimmune Polyglandular Syndrome Type 1 Market Size, Share & Trends Analysis Report By Diagnosis (Serum Autoimmune Screen, End-organ Function Tests, Blood Tests, Others), Age of Onset (Childhood, Adult, Adolescent), Treatment (Medication, Hormone Replacement Therapy, Others), Dosage Form (Tablet, Capsule, Others), Route of Administration, End-Users, Distribution Channel, By Region, And By Segment Forecasts, 2024-2031
Segmentation of Autoimmune Polyglandular Syndrome Type 1 Market -
Autoimmune Polyglandular Syndrome Type 1 Market By Diagnosis-
- Serum Autoimmune Screen
- End-organ Function Tests
- Blood Tests
- Others
Autoimmune Polyglandular Syndrome Type 1 Market By Treatment-
- Medication
- Hormone Replacement Therapy
- Others
Autoimmune Polyglandular Syndrome Type 1 Market By Dosage Form-
- Tablet
- Capsule
- Others
Autoimmune Polyglandular Syndrome Type 1 Market By Route of Administration-
- Oral
- Others
Autoimmune Polyglandular Syndrome Type 1 Market By Age of Onset -
- Childhood,
- Adult,
- Adolescent
Autoimmune Polyglandular Syndrome Type 1 Market By End-User
- Hospitals
- Specialty Clinics
- Homecare
- Others
Autoimmune Polyglandular Syndrome Type 1 Market By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Autoimmune Polyglandular Syndrome Type 1 Market By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Autoimmune Polyglandular Syndrome Market Snapshot
Chapter 4. Global Autoimmune Polyglandular Syndrome Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Diagnosis Estimates & Trend Analysis
5.1. by Diagnosis & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Diagnosis:
5.2.1. Serum Autoimmune Screen
5.2.2. End-organ Function Tests
5.2.3. Blood Tests
5.2.4. Others
Chapter 6. Market Segmentation 2: by Treatment Estimates & Trend Analysis
6.1. by Treatment & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Treatment:
6.2.1. Medication
6.2.2. Antifungal Agents
6.2.3. Fluconazole
6.2.4. Itraconazole
6.2.5. Calcitriol
6.2.6. Corticosteroids
6.2.7. Hormone Replacement Therapy
6.2.8. Others
Chapter 7. Market Segmentation 3: by Dosage Form Estimates & Trend Analysis
7.1. by Dosage Form & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Dosage Form:
7.2.1. Tablet
7.2.2. Capsule
7.2.3. Others
Chapter 8. Market Segmentation 4: by Route of Administration Estimates & Trend Analysis
8.1. by Route of Administration & Market Share, 2019 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Route of Administration;
8.2.1. Oral
8.2.2. Others
Chapter 9. Market Segmentation 5: by Age of Onset Estimates & Trend Analysis
9.1. by Age of Onset & Market Share, 2019 & 2031
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Age of Onset;
9.2.1. Childhood
9.2.2. Adult
9.2.3. Adolescent
Chapter 10. Market Segmentation 6: by Distribution Channel Estimates & Trend Analysis
10.1. by Distribution Channel & Market Share, 2019 & 2031
10.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Distribution Channel;
10.2.1. Hospital Pharmacy
10.2.2. Retail Pharmacy
10.2.3. Online Pharmacy
10.2.4. Others
Chapter 11. Market Segmentation 7: by End-Users Estimates & Trend Analysis
11.1. by End-Users & Market Share, 2019 & 2031
11.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-Users:
11.2.1. Hospitals
11.2.2. Specialty Clinics
11.2.3. Homecare
11.2.4. Others
Chapter 12. Autoimmune Polyglandular Syndrome Market Segmentation 8: Regional Estimates & Trend Analysis
12.1. North America
12.1.1. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
12.1.2. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2019-2031
12.1.3. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2019-2031
12.1.4. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
12.1.5. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Age of Onset, 2019-2031
12.1.6. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
12.1.7. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
12.1.8. North America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
12.2. Europe
12.2.1. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
12.2.2. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2019-2031
12.2.3. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2019-2031
12.2.4. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
12.2.5. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Age of Onset, 2019-2031
12.2.6. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
12.2.7. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
12.2.8. Europe Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
12.3. Asia Pacific
12.3.1. Asia Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
12.3.2. Asia Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2019-2031
12.3.3. Asia-Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2019-2031
12.3.4. Asia Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
12.3.5. Asia Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Age of Onset, 2019-2031
12.3.6. Asia Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
12.3.7. Asia Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
12.3.8. Asia Pacific Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
12.4. Latin America
12.4.1. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
12.4.2. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2019-2031
12.4.3. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2019-2031
12.4.4. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration,2019-2031
12.4.5. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Age of Onset, 2019-2031
12.4.6. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
12.4.7. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
12.4.8. Latin America Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
12.5. Middle East & Africa
12.5.1. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2019-2031
12.5.2. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2019-2031
12.5.3. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2019-2031
12.5.4. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
12.5.5. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Age of Onset, 2019-2031
12.5.6. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
12.5.7. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
12.5.8. Middle East & Africa Autoimmune Polyglandular Syndrome Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 13. Competitive Landscape
13.1. Major Mergers and Acquisitions/Strategic Alliances
13.2. Company Profiles
13.2.1. Pfizer Inc. (U.S.)
13.2.2. GlaxoSmithKline plc (U.K.)
13.2.3. Novartis AG (Switzerland)
13.2.4. Mylan N.V. (U.S.)
13.2.5. Teva Pharmaceutical Industries Ltd
13.2.6. Sanofi (France)
13.2.7. F. Hoffmann-La Roche Ltd. (Switzerland)
13.2.8. Zydus Cadila (India)
13.2.9. Lupin (India)
13.2.10. Amneal Pharmaceuticals LLC. (U.S.)
13.2.11. Cipla Inc. (U.S.)
13.2.12. Aurobindo Pharma (India)
13.2.13. Glenmark Pharmaceuticals Limited
13.2.14. Eli Lilly and Company (U.S.)
13.2.15. Sun Pharmaceutical Industries Ltd.
13.2.16. Allergan (Ireland)
13.2.17. Bristol-Myers Squibb Company (U.S.)
13.2.18. Takeda Pharmaceutical Company Limited
13.2.19. Abbott (U.S.)
13.2.20. LEO Pharma A/S (Denmark)
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Autoimmune Polyglandular Syndrome Type 1 Market Size is valued at USD 244.1 Mn in 2023 and is predicted to reach USD 389.6 Mn by the year 2031
Autoimmune Polyglandular Syndrome Type 1 Market at a 6.20% CAGR during the forecast period for 2024-2031.
Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Allergan, Bristol-Myers Squibb Company, Takeda Pharmaceut